Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by McMaster University.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Food Allergy Initiative
AllerGen NCE Inc.
Information provided by:
McMaster University
ClinicalTrials.gov Identifier:
NCT00243555
First received: October 20, 2005
Last updated: January 31, 2007
Last verified: September 2006
  Purpose

The purpose of this study is to develop a tool to better predict clinical allergy to peanut, so that those who are skin test positive but non allergic will not have to unnecessarily avoid peanut, and those with true allergy can be diagnosed, possibly without oral ingestion challenge, and treated appropriately


Condition Intervention
Peanut Hypersensitivity
Procedure: allergy skin testing
Procedure: venepuncture

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Molecular Analysis of Immuno-Regulatory Genes Expressed by Mononuclear Cells From Peanut Skin Test Positive Individuals With and Without a History of Peanut Ingestion

Resource links provided by NLM:


Further study details as provided by McMaster University:

Estimated Enrollment: 60
Study Start Date: September 2002
Detailed Description:

Peanut allergy occurs in about 1% of the population. Allergic reactions to peanuts and tree nuts account for the majority of fatal and near fatal food allergic reactions. Currently the only available treatment is complete avoidance of peanut. Despite avoidance, the majority of peanut allergic people will accidentally ingest peanut. Accurate diagnosis is critical, yet often problematic. Current diagnostic methods such as skin and blood tests cannot predict definitively who is allergic and can result in patients being falsely labeled. One such group is children who have never been exposed to peanut as a means of preventing allergy, yet have positive skin tests. The only means of definitively diagnosing this group is with an oral peanut challenge, a potentially risky procedure. Previous studies have demonstrated differences in certain genes and growth factors between peanut allergic and non-allergic individuals. The proposed study has 2 phases. The first phase, almost completed, examines expression of genes and growth factors in defined groups of peanut allergic and non-allergic individuals which should help distinguish between these groups. Peripheral blood mononuclear cells from each patient will be cultured and analyzed for a variety of growth factors and other immune molecules, including mRNA, thought to be important in allergy.

The second phase of this study will involve feeding peanut to individuals with positive skin tests, who have never been peanut exposed. Their blood will be examined before and after the challenge using information from Part 1, and results will be correlated with their ability to tolerate peanut on feeding. This study should enable us to better predict who is truly peanut allergic.

There are four groups of patients in this study. Group 1 consists of individuals who are allergic to peanut. This group of individuals will have a positive skin test to peanut and a previous allergi reaction to peanut. Group 2 consists of indivduals who have a positive skin test to peanut but who are able to ingest peanuts without problems. Group 3 consists of individuals who have a positive skin test to peanut but who have no known ingestion of peanut and who have avoided peanut lifelong for whatever reason (e.g. a strong family history of peanut allergy). Lastly, group 4 consists of control subjects who are negative to the peanut skin test and are able to tolerate peanut without problems.

  Eligibility

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 5 years of age and older
  • Informed consent (Subject has provided an appropriately signed and dated informed consent. An appropriately signed and dated assent must be obtained from the parents or guardian if the subject is a child under 18 years of age.)
  • Free of any clinically significant disease, such as uncontrolled asthma, which may interfere with study evaluations

Group 1:

  • skin test positive to peanut
  • documented clinical history of peanut allergy. A documented clinical history may include symptoms such as hives,swelling of the mouth or tongue, throat closing sensation, shortness of breath, wheezing, lightheadedness, anaphylaxis.

Group 2:

  • Positive skin test to peanut
  • History of being able to tolerate peanut exposure without problems

Group 3:

  • Positive skin test to peanut
  • No known ingestion of peanut

Group 4:

  • Negative skin test to peanut
  • Negative skin test to other food and environmental allergens
  • Able to tolerate peanut exposure without problems

Exclusion Criteria:

  • Women who are pregnant or nursing
  • use of antihistamines or decongestant therapy four days prior to clinic visit
  • use of nasal or inhaled corticosteroid in the 1 month period prior to clinic visit
  • use of non-steroidal anti-inflammatory drugs (NSAIDS) in the week prior to clinic visit
  • Moderate or severe/ uncontrolled asthma (defined as the use of more than 4 puffs of ventolin per day, not including prophylactic medications prior to exercise)
  • Symptomatic allergic rhinitis
  • Patients who had an acute allergic reaction to food, drugs, and bee sting in the 1 month period prior to clinic visit
  • Use of an epi-pen during the past month
  • respiratory infection one month prior to clinic visit
  • immunotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00243555

Contacts
Contact: Andrea Marin, MD 905-521-2100 ext 75642

Locations
Canada, Ontario
Hamilton Health Sciences Corporation, McMaster Site Recruiting
Hamilton, Ontario, Canada, L8N 3Z5
Contact: Marie Townsend    905-525-9140 ext 22465    hsresadm@mcmaster.ca   
Contact: Deidre L. Henne    905-521-2100 ext 74595    henne@hhsc.ca   
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Food Allergy Initiative
AllerGen NCE Inc.
Investigators
Principal Investigator: Susan Waserman, MSc, MD, FRCPC Hamilton Health Sciences Corporation, McMaster Site
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00243555     History of Changes
Other Study ID Numbers: 2002H05183, FP-2005-25
Study First Received: October 20, 2005
Last Updated: January 31, 2007
Health Authority: Canada: Health Canada

Keywords provided by McMaster University:
peanut hypersensitivity
chemokines
cytokines
RNA,messenger
monocytes

Additional relevant MeSH terms:
Hypersensitivity
Peanut Hypersensitivity
Immune System Diseases
Food Hypersensitivity
Hypersensitivity, Immediate

ClinicalTrials.gov processed this record on September 14, 2014